FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386961531> ?p ?o ?g. }

• W4386961531 endingPage "2367" @default.
• W4386961531 startingPage "2367" @default.
• W4386961531 abstract "Currently, the main pillars in treating breast cancer involve tumorectomy pursued by hormonal, radio, or chemotherapies. Nonetheless, these approaches exhibit severe adverse effects and might suffer from tumor recurrence. Therefore, there is a considerable demand to fabricate an innovative controlled-release nano-delivery system to be implanted after tumor surgical removal to guard against cancer recurrence. In addition, combining platinum-based drugs with phytochemicals is a promising approach to improving the anticancer activity of the chemotherapeutics against tumor cells while minimizing their systemic effects. This study designed polycaprolactone (PCL)-based electrospun nanofiber mats encapsulating nedaplatin (N) and Peganum harmala alkaloid-rich fraction (L). In addition to physicochemical characterization, including average diameters, morphological features, degradation study, thermal stability, and release kinetics study, the formulated nanofibers were assessed in terms of cytotoxicity, where they demonstrated potentiated effects and higher selectivity towards breast cancer cells. The dual-loaded nanofiber mats (N + L@PCL) demonstrated the highest antiproliferative effects against MCF-7 cells with a recorded IC50 of 3.21 µg/mL, as well as the topmost achieved selectivity index (20.45) towards cancer cells amongst all the tested agents (N, L, N@PCL, and L@PCL). This indicates that the dual-loaded nanofiber excelled at conserving the normal breast epithelial cells (MCF-10A). The combined therapy, N + L@PCL treatment, resulted in a significantly higher percent cell population in the late apoptosis and necrosis quartiles as compared to all other treatment groups (p-value of ≤0.001). Moreover, this study of cell cycle kinetics revealed potentiated effects of the dual-loaded nanofiber (N + L@PCL) at trapping more than 90% of cells in the sub-G1 phase and reducing the number of cells undergoing DNA synthesis in the S-phase by 15-fold as compared to nontreated cells; hence, causing cessation of the cell cycle and confirming the apoptosis assay results. As such, our findings suggest the potential use of the designed nanofiber mats as perfect implants to prevent tumor recurrence after tumorectomy." @default.
• W4386961531 created "2023-09-23" @default.
• W4386961531 creator A5002348525 @default.
• W4386961531 creator A5005764434 @default.
• W4386961531 creator A5008450363 @default.
• W4386961531 creator A5009711256 @default.
• W4386961531 creator A5021453491 @default.
• W4386961531 creator A5052347763 @default.
• W4386961531 creator A5076318072 @default.
• W4386961531 creator A5078839649 @default.
• W4386961531 creator A5083637463 @default.
• W4386961531 date "2023-09-22" @default.
• W4386961531 modified "2023-09-29" @default.
• W4386961531 title "Nedaplatin/Peganum harmala Alkaloids Co-Loaded Electrospun, Implantable Nanofibers: A Chemopreventive Nano-Delivery System for Treating and Preventing Breast Cancer Recurrence after Tumorectomy" @default.
• W4386961531 cites W1897256676 @default.
• W4386961531 cites W1979296105 @default.
• W4386961531 cites W1984418916 @default.
• W4386961531 cites W1988600420 @default.
• W4386961531 cites W1989010842 @default.
• W4386961531 cites W2000374713 @default.
• W4386961531 cites W2003864069 @default.
• W4386961531 cites W2032032896 @default.
• W4386961531 cites W2101539565 @default.
• W4386961531 cites W2127721169 @default.
• W4386961531 cites W2133838296 @default.
• W4386961531 cites W2157976579 @default.
• W4386961531 cites W2275458638 @default.
• W4386961531 cites W2321986134 @default.
• W4386961531 cites W2326360526 @default.
• W4386961531 cites W2593133309 @default.
• W4386961531 cites W2789318818 @default.
• W4386961531 cites W2804904048 @default.
• W4386961531 cites W2887024609 @default.
• W4386961531 cites W2903613218 @default.
• W4386961531 cites W2942497294 @default.
• W4386961531 cites W2981003756 @default.
• W4386961531 cites W2982959036 @default.
• W4386961531 cites W2988183882 @default.
• W4386961531 cites W2991971207 @default.
• W4386961531 cites W3093657652 @default.
• W4386961531 cites W3111002297 @default.
• W4386961531 cites W3120753883 @default.
• W4386961531 cites W3157355350 @default.
• W4386961531 cites W3190250292 @default.
• W4386961531 cites W3195417419 @default.
• W4386961531 cites W3207981557 @default.
• W4386961531 cites W3211312625 @default.
• W4386961531 cites W3212696981 @default.
• W4386961531 cites W3214400699 @default.
• W4386961531 cites W4205266351 @default.
• W4386961531 cites W4205689492 @default.
• W4386961531 cites W4213250810 @default.
• W4386961531 cites W4213275074 @default.
• W4386961531 cites W4223600067 @default.
• W4386961531 cites W4283806105 @default.
• W4386961531 cites W4284991310 @default.
• W4386961531 cites W4296127374 @default.
• W4386961531 cites W4296588609 @default.
• W4386961531 cites W4307601328 @default.
• W4386961531 cites W4308410742 @default.
• W4386961531 cites W4313422624 @default.
• W4386961531 cites W4327600927 @default.
• W4386961531 cites W4328049831 @default.
• W4386961531 cites W4366770909 @default.
• W4386961531 cites W4376630315 @default.
• W4386961531 doi "https://doi.org/10.3390/pharmaceutics15102367" @default.
• W4386961531 hasPublicationYear "2023" @default.
• W4386961531 type Work @default.
• W4386961531 citedByCount "0" @default.
• W4386961531 crossrefType "journal-article" @default.
• W4386961531 hasAuthorship W4386961531A5002348525 @default.
• W4386961531 hasAuthorship W4386961531A5005764434 @default.
• W4386961531 hasAuthorship W4386961531A5008450363 @default.
• W4386961531 hasAuthorship W4386961531A5009711256 @default.
• W4386961531 hasAuthorship W4386961531A5021453491 @default.
• W4386961531 hasAuthorship W4386961531A5052347763 @default.
• W4386961531 hasAuthorship W4386961531A5076318072 @default.
• W4386961531 hasAuthorship W4386961531A5078839649 @default.
• W4386961531 hasAuthorship W4386961531A5083637463 @default.
• W4386961531 hasBestOaLocation W43869615311 @default.
• W4386961531 hasConcept C121608353 @default.
• W4386961531 hasConcept C126322002 @default.
• W4386961531 hasConcept C171250308 @default.
• W4386961531 hasConcept C185592680 @default.
• W4386961531 hasConcept C192562407 @default.
• W4386961531 hasConcept C203014093 @default.
• W4386961531 hasConcept C2775930923 @default.
• W4386961531 hasConcept C2778250585 @default.
• W4386961531 hasConcept C2780237542 @default.
• W4386961531 hasConcept C530470458 @default.
• W4386961531 hasConcept C71924100 @default.
• W4386961531 hasConcept C91129048 @default.
• W4386961531 hasConcept C96232424 @default.
• W4386961531 hasConcept C98274493 @default.
• W4386961531 hasConceptScore W4386961531C121608353 @default.
• W4386961531 hasConceptScore W4386961531C126322002 @default.
• W4386961531 hasConceptScore W4386961531C171250308 @default.
• W4386961531 hasConceptScore W4386961531C185592680 @default.

• next